Chiara Pircher
About
Chiara Pircher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Chiara Pircher has authored 22 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Chiara Pircher's work include Pancreatic and Hepatic Oncology Research (12 papers), Cancer Genomics and Diagnostics (12 papers) and Renal cell carcinoma treatment (9 papers). Chiara Pircher is often cited by papers focused on Pancreatic and Hepatic Oncology Research (12 papers), Cancer Genomics and Diagnostics (12 papers) and Renal cell carcinoma treatment (9 papers). Chiara Pircher collaborates with scholars based in Italy, Germany and United Kingdom. Chiara Pircher's co-authors include Silvia Zanon, Michele Reni, Luca Gianni, Gianpaolo Balzano, Marta Chiaravalli, Claudio Doglioni, Massimo Falconi, Domenica Ceraulo, Paolo Giorgio Arcidiacono and R. Castoldi and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.
In The Last Decade
Chiara Pircher
19 papers receiving 389 citations
Hit Papers
Peers
Chiara Pircher
Julien Volet France
Stefano Ferrara United States
Jörg Seraphin Germany
Richard A. Burkhart United States
Milena Sachsenmaier Germany
Tom Crosby United Kingdom
Quisette P. Janssen Netherlands
J. Boukovinas Greece
Matthew J. Iott United States
J. Garde Spain
Citations per year, relative to Chiara Pircher Chiara Pircher (= 1×)
peers
Julien Volet
Countries citing papers authored by Chiara Pircher
Since
Specialization
Citations
This map shows the geographic impact of Chiara Pircher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Pircher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Pircher more than expected).
Fields of papers citing papers by Chiara Pircher
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chiara Pircher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Pircher. The network helps show where Chiara Pircher may publish in the future.
Co-authorship network of co-authors of Chiara Pircher
This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Pircher. A scholar is included among the top collaborators of Chiara Pircher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Pircher. Chiara Pircher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ballhausen, Alexej, Federica Morano, Arndt Stahler, et al.. (2025). Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials. British Journal of Cancer. 133(9). 1297–1306.
2.
Raimondi, Alessandra, David Tougeron, Sara Lonardi, et al.. (2025). Individual patient data (IPD) pooled analysis on the optimal therapeutic management of patients with microsatellite instability-high (MSI) resectable gastroesophageal adenocarcinoma (GEA).. Journal of Clinical Oncology. 43(4_suppl). 455–455.
3.
Nichetti, Federico, Chiara Pircher, Michele Droz Dit Busset, et al.. (2024). NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer. JAMA Network Open. 7(1). e2350756–e2350756.
4.
Sepe, Pierangela, Giuseppe Procopio, Chiara Pircher, et al.. (2024). A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study). Therapeutic Advances in Medical Oncology. 16. 2662694–2662694.
5.
Bourien, Héloïse, Chiara Pircher, Boris Guiu, et al.. (2023). Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?. Cancers. 15(17). 4217–4217.
6.
Nichetti, Federico, et al.. (2023). NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials.. Journal of Clinical Oncology. 41(16_suppl). e16262–e16262.
7.
Nichetti, Federico, Andrea Vingiani, Chiara Pircher, et al.. (2023). Evaluation of clinical benefit and progression-free survival ratio of targeted treatments in a prospective cohort study of patients with biliary tract cancers.. Journal of Clinical Oncology. 41(4_suppl). 590–590.
8.
Sepe, Pierangela, Marco Stellato, Chiara Pircher, et al.. (2022). Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Cancer Management and Research. Volume 14. 3071–3081.
9.
Sepe, Pierangela, Chiara Pircher, Mélanie Claps, et al.. (2021). Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. Cancers. 13(15). 3807–3807.
10.
Procopio, Giuseppe, Chiara Pircher, Mélanie Claps, et al.. (2021). A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).. Journal of Clinical Oncology. 39(6_suppl). 326–326.
11.
Procopio, Giuseppe, Mélanie Claps, Chiara Pircher, et al.. (2021). A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).. Journal of Clinical Oncology. 39(15_suppl). 4569–4569.
12.
Macchini, Marina, Marta Chiaravalli, Chiara Pircher, et al.. (2020). Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease. 53(1). 117–121.
13.
Nichetti, Federico, Margherita Ambrosini, Rita Leporati, et al.. (2020). COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. ESMO Open. 5(Suppl 3). e000883–e000883.
14.
Reni, Michele, Gianpaolo Balzano, Silvia Zanon, et al.. (2018). Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. The Lancet. Gastroenterology & hepatology. 3(6). 413–423.
15.
Reni, Michele, Silvia Zanon, Umberto Peretti, et al.. (2018). Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet. Gastroenterology & hepatology. 3(10). 691–697.
16.
Reni, Michele, Silvia Zanon, Gianpaolo Balzano, et al.. (2018). A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer. 102. 95–102.
17.
Zanon, Silvia, Chiara Pircher, Marina Macchini, et al.. (2017). Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma. Annals of Oncology. 28. vi44–vi45.
18.
Reni, Michele, Silvia Zanon, Chiara Pircher, et al.. (2017). Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma. Annals of Oncology. 28. v252–v252.
19.
Reni, Michele, Silvia Zanon, Gianpaolo Balzano, et al.. (2016). Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma. Annals of Oncology. 27. vi230–vi230.
20.
Reni, Michele, Silvia Zanon, Gianpaolo Balzano, et al.. (2016). A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back. Annals of Oncology. 27. iv17–iv17.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Julien Volet Breakdown of academic impact, for papers by Stefano Ferrara Breakdown of academic impact, for papers by Jörg Seraphin Breakdown of academic impact, for papers by Richard A. Burkhart Breakdown of academic impact, for papers by Milena Sachsenmaier Breakdown of academic impact, for papers by Tom Crosby Breakdown of academic impact, for papers by Quisette P. Janssen Breakdown of academic impact, for papers by J. Boukovinas Breakdown of academic impact, for papers by Matthew J. Iott Breakdown of academic impact, for papers by J. Garde